PerkinElmer (NYSE: PKI) and Precipio (NASDAQ:PRPO) are both computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Earnings and Valuation
This table compares PerkinElmer and Precipio’s revenue, earnings per share and valuation.
||Earnings Per Share
PerkinElmer has higher revenue and earnings than Precipio.
This table compares PerkinElmer and Precipio’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Precipio does not pay a dividend. PerkinElmer pays out 9.7% of its earnings in the form of a dividend.
This is a summary of recent ratings for PerkinElmer and Precipio, as reported by MarketBeat.com.
||Strong Buy Ratings
PerkinElmer presently has a consensus target price of $76.95, suggesting a potential downside of 1.72%. Given PerkinElmer’s higher probable upside, research analysts plainly believe PerkinElmer is more favorable than Precipio.
Volatility and Risk
PerkinElmer has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Precipio has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Institutional & Insider Ownership
93.6% of PerkinElmer shares are owned by institutional investors. Comparatively, 11.4% of Precipio shares are owned by institutional investors. 2.1% of PerkinElmer shares are owned by insiders. Comparatively, 13.1% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
PerkinElmer beats Precipio on 10 of the 13 factors compared between the two stocks.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.
Precipio, Inc. provides platform to eradicate the problem of misdiagnosis within academic institutions. The company also delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.